Therapeutic Potential of Human Mesenchymal Stem Cells in Osteoarthritis

Abstract: 

Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage breakdown, inflammation, and loss of joint function. While current treatments primarily target symptom relief, they fail to halt or reverse disease progression. Human mesenchymal stem cells (hMSCs) have emerged as promising regenerative agents due to their dual capacity for chondrogenic differentiation and immunomodulation. This review examines the therapeutic potential of hMSCs in OA treatment, emphasizing their biological mechanisms, clinical relevance, and translational barriers. Preclinical evidence highlights that in addition to their differentiation into cartilage-forming cells, hMSCs exert potent paracrine effects through the secretion of cytokines, growth factors, and extracellular vesicles such as exosomes. Studies demonstrate that these vesicles play a central role in reducing inflammation, protecting cartilage matrix integrity, and promoting tissue repair. Adjunctive interventions like low-intensity pulsed ultrasound (LIPUS) further enhance the chondrogenic efficacy of hMSCs, offering combinatorial strategies for improving therapeutic outcomes. Nevertheless, translational challenges persist, including donor variability, inconsistent manufacturing protocols, and the absence of standardized potency assays. As research advances, exosome-based therapies are gaining traction as safer, cell-free alternatives that preserve the functional benefits of hMSCs while addressing many logistical and regulatory concerns. Collectively, these findings suggest that hMSCs—particularly through paracrine and exosome-mediated mechanisms—represent a promising avenue in the development of disease-modifying treatments for osteoarthritis.